Abbisko Signs an Exclusive License Agreement with Sperogenix to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China

Abbisko Indications an Exclusive License Agreement with Sperogenix to Establish ABSK021 for ALS and Other Uncommon Neurological Illness in Greater China

Shots:

Abbisko to receive upfront, milestones and royalties on net sales of the treatment & & hold the rights for all other countries & & indications. Sperogenix gets an unique right to establish, produce & & advertise ABSK021 in mainland China, Hong Kong SAR and Macao SAR for non-oncology uncommon neurological illness
Sperogenix will be responsible for the development of ABSK021 in ALS includes pre/ scientific studies, registration & & commercialization of the product in the Sperogenix Territory
ABSK021 is a selective CSF-1R villain. The P-Ib trial has actually started to assess security, tolerability & & PK of ABSK021 in China & & the US while initial data demonstrate that ABSK021 was well tolerated

Click here to read complete news release/ short article|Ref: PR Newswire|Image: Abbisko

Post Views:
2